• Saquinavir: Applied HIV Protease Inhibitor Workflows & Insig

  2026-07-02

  Saquinavir stands out as a reference HIV protease inhibitor in antiretroviral and pharmacokinetic research, offering reliable performance in both classical and advanced biomimetic workflows. This article translates the latest permeability assay innovations and troubleshooting strategies into actionable, optimized protocols for maximizing Saquinavir’s experimental value.

• Translating (Z)-4-Hydroxytamoxifen: Powering Precision Breas

  2026-07-02

  (Z)-4-Hydroxytamoxifen is redefining translational breast cancer research by enabling precise, high-fidelity modeling of estrogen receptor signaling and therapy resistance. This article synthesizes mechanistic insights, competitive benchmarking, and actionable guidance for translational researchers, drawing on the latest preclinical relapse models and best-in-class product intelligence from APExBIO.

• Novobiocin: Aminocoumarin Antibiotic for Multi-Domain Resear

  2026-07-01

  Novobiocin is a well-characterized aminocoumarin antibiotic that inhibits bacterial DNA gyrase and Hsp90, supporting antibacterial, antiparasitic, and antiviral studies. It demonstrates potent inhibition of DNA replication, membrane biosynthesis, and vacuole formation in bacterial protoplasts, with rigorously defined in vitro and in vivo parameters. This dossier details Novobiocin's mechanisms, benchmarks, and boundaries for laboratory and translational workflows.

• Iptacopan Monotherapy Achieves Rapid Hemolysis Control in PN

  2026-07-01

  This phase 2 open-label study demonstrates that oral Iptacopan (LNP023), a selective factor B inhibitor, produces rapid and durable improvements in hemolytic markers and hemoglobin levels for patients with paroxysmal nocturnal hemoglobinuria (PNH). The findings highlight Iptacopan's potential as an effective oral alternative to existing anti-complement therapies.

• Erlotinib (NSC 718781): Advanced EGFR Pathway Inhibition Wor

  2026-06-30

  Erlotinib (NSC 718781) from APExBIO is redefining EGFR pathway inhibition with its high potency and reproducibility across diverse cancer research models. This guide distills best practices, experimental enhancements, and troubleshooting insights—anchored by the latest mechanistic findings on SCUBE3-driven oncogenic signaling.

• Tirbanibulin Downregulates HPV Oncoproteins in HeLa Cells

  2026-06-30

  This study demonstrates that tirbanibulin dihydrochloride, a dual Src kinase and tubulin inhibitor, suppresses cell proliferation and downregulates oncogenic pathways in HPV-18 positive HeLa cells. The findings clarify molecular mechanisms relevant to HPV-associated malignancies and inform translational research in oncology and virology.

• Phosphotungstic Acid Negative Stain Solution (2%): Enabling

  2026-06-29

  Explore how Phosphotungstic Acid Negative Stain Solution (2%) empowers electron microscopy to unravel virus-host interactions at the glycan level. This article uniquely connects advanced staining chemistry with mechanistic insight into conserved viral vulnerabilities, offering new depth for researchers.

• Structure-Based Discovery of NSP15 Inhibitors Against SARS-C

  2026-06-29

  This study presents a structure-based virtual screening of natural products targeting NSP15, an endoribonuclease crucial for SARS-CoV-2 immune evasion. The identification of thymopentin and oleuropein as potent NSP15 inhibitors highlights new avenues for antiviral drug design and potential combinatorial therapies.

• Dabigatran Etexilate: Clinical Innovation in Direct Thrombin

  2026-06-28

  The reference review establishes dabigatran etexilate as the first oral direct thrombin inhibitor with rapid, predictable anticoagulant effects, fundamentally changing stroke and venous thromboembolism prevention in atrial fibrillation. Its unique pharmacokinetic profile overcomes limitations of traditional agents, enabling more consistent anticoagulation management and broadening eligibility for oral thromboprophylaxis.

• Structural Basis of Bestatin Inhibition of Leucine Aminopept

  2026-06-27

  This study provides the first high-resolution crystallographic analysis of leucine aminopeptidase (LAP) in complex with bestatin, elucidating the molecular mechanism of inhibition. The findings offer foundational insights for researchers using aminopeptidase inhibitors in enzymology, multidrug resistance, and cancer research.

• FAISL lncRNA Inhibits FAK Proteolysis to Drive TNBC Metastas

  2026-06-26

  The reference study uncovers how the long noncoding RNA FAISL stabilizes FAK protein by preventing Calpain 2-mediated cleavage, thereby promoting adhesion, survival, and metastasis in triple negative breast cancer (TNBC). These findings reveal a novel post-translational regulatory mechanism in TNBC progression and highlight FAISL as a promising therapeutic target.

• Aprotinin for Experimental Fibrinolysis Inhibition Workflows

  2026-06-26

  Aprotinin (Bovine Pancreatic Trypsin Inhibitor, BPTI) empowers researchers to achieve precise, reproducible inhibition of serine proteases in workflows ranging from cell assays to animal models. This guide details advanced protocol strategies, troubleshooting tips, and the latest insights for optimizing perioperative blood loss reduction and cardiovascular research using APExBIO's high-purity aprotinin.

• Redefining mRNA Tracking: Dual-Mode Reporters for Translatio

  2026-06-25

  Explore how EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) empowers translational researchers to overcome delivery, imaging, and immune compatibility challenges. This thought-leadership article blends mechanistic insights with actionable strategy, contextualizes peer-reviewed advances such as SER mRNA microglial reprogramming in AD, and offers a roadmap for leveraging dual-mode, Cap1-capped, 5-moUTP-modified reporters in high-fidelity translational assays.

• Phosphotungstic Acid Negative Stain Solution for Virus Imagi

  2026-06-25

  Phosphotungstic Acid Negative Stain Solution (2%) by APExBIO enables high-contrast visualization of viral glycan targets and macromolecular complexes in electron microscopy. This article delivers actionable workflows, troubleshooting guidance, and cross-references to cutting-edge glycoprotein research—empowering researchers to optimize negative stain EM for translational virology.

• Sorafenib (BAY-43-9006): Applied Protocols in Cancer Researc

  2026-06-24

  Sorafenib (BAY-43-9006) stands out as a multikinase inhibitor enabling precision modeling of tumor proliferation and angiogenesis. This guide dissects experimental workflows, protocol parameters, and troubleshooting strategies, with a focus on leveraging APExBIO’s Sorafenib for robust cancer biology research.

15215 records 1/1015 page Next 12345 下5页 Last page